reports
- Ari Zoldan
Pluri Inc. - Initiation of Coverage
Pluri Inc. is a biotechnology company leveraging proprietary 3D cell expansion technology to provide scalable cell-based solutions across regenerative medicine, food technology, contract development and manufacturing (CDMO), and agricultural sectors. The company's innovative PluriMatrix platform, utilizing an automated cGMP-approved bioreactor system, ensures high-quality, consistent, and cost-effective industrial-scale cell production applicable to pharmaceuticals, biologics, cultivated foods, ...
- Ari Zoldan
ALZHEIMER’S DISEASE STATE OF PLAY WITH FOCUS ON SIMILARITIES BETWEEN M...
There are large unmet medical needs for the treatment of Alzheimer’s disease. The efficacy of treatments should improve, and combination therapies should be considered, whether or not they’re focused on the biology of aging. Additionally, side effects can be reduced, and further-advanced patient groups should be able to receive treatment as well. Over the past two years, four publicly listed companies have reported data that seem to indicate that the progression of Alzheimer’s disease can be sto...
- Ari Zoldan
Coya Therapeutics (NASDAQ: COYA) - Company Update
Coya Therapeutics recently announced the results from its POC open-label study evaluating COYA 301, a low-dose IL-2 treatment, in patients with Alzheimer’s disease. The trial showed promising results, with statistically significant improvements in cognition on the Mini-Mental State Examination (MMSE) scale, improved Treg population and functionality, and lower levels of pro-inflammatory biomarkers at the end of the treatment regimen. Considering the company’s ability to replicate encouraging res...
- Ari Zoldan
BioVie Inc. (NASDAQ: BIVI) - Company Note
In the past six months, BioVie has gained considerable attention from the market due to NE3107’s promising clinical findings in Alzheimer’s disease (AD) and Parkinson’s disease (PD). These findings were further bolstered by the recent announcement of statistically significant and robust efficacy data for BIV-201 in patients with refractory ascites. Both clinical candidates are in the advanced clinical phase and have the potential to address significant unmet needs in their respective therapeutic...
- Ari Zoldan
Coya Therapeutics (NASDAQ: COYA)
The company's diverse pipeline of Treg-modulating candidates seeks to restore immune balance by targeting inflammation, a common and critical factor in the progression of numerous neurodegenerative diseases (NDDs) and autoimmune diseases. Coya aims to treat 1.7 million patients across the U.S., with a total addressable market exceeding $7 billion. Moreover, Coya recently reported encouraging results from its proof-of-concept study in ALS patients. COYA 302 effectively slowed disease progression,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.